Filing Flows

Filing Flows › Companies › Praxis Precision Medicines › Cash flow

Praxis Precision Medicines cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$77.8M in Q2 2026 · −$305M over twelve months

Operating cash flow−$77.5M
Capital spending−$245K
Free cash flow−$77.8M

Analysis

In Q2 2026, Praxis Precision Medicines generated −$77.5M of operating cash flow and spent $245K on capital projects, leaving free cash flow of −$77.8M. That is $23.1M less than in Q2 2025 (−$54.7M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$305M; the largest uses were other financing ($1.8B), other investing ($611M), operating cash flow ($305M); besides operations, cash came from shares issued ($3.0B); the cash balance rose by $317M.

Operating cash flow was −$77.5M against net income of −$83.7M. The largest differences: stock-based pay +$11.3M, payables −$7.9M, accrued liabilities +$6.9M.

Free cash flow

Praxis Precision Medicines: free cash flow by quarterPraxis Precision Medicines: free cash flow by quarter−$27.5MQ3 2024−$56.1MQ4 2024−$53.0MQ1 2025−$54.7MQ2 2025−$65.1MQ3 2025−$76.3MQ4 2025−$86.2MQ1 2026−$77.8MQ2 2026
Operating cash flow less capital spending.
Praxis Precision Medicines: operating cash flow against capital spendingPraxis Precision Medicines: operating cash flow against capital spendingOperating cash flowCapital spending−$27.5M$0Q3 2024−$56.1M$0Q4 2024−$53.0M$0Q1 2025−$54.7M$56KQ2 2025−$65.1M$0Q3 2025−$76.3M$0Q4 2025−$86.2M$62KQ1 2026−$77.5M$245KQ2 2026
Latest (Q2 2026): Operating cash flow −$77.5M, Capital spending $245K.

Capital allocation, year by year

Praxis Precision Medicines: where the cash came from (up) and went (down), by fiscal yearPraxis Precision Medicines: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$125MFY2021: Shares issued $101MFY2021: Capital spending −$1.1M$101MFY2021FY2022: Operating cash flow −$185MFY2022: Shares issued $1.4MFY2022: Capital spending −$444K$1.4MFY2022FY2023: Operating cash flow −$111MFY2023: Shares issued $618MFY2023: Capital spending −$50K$618MFY2023FY2024: Operating cash flow −$132MFY2024: Shares issued $1.1B$1.1BFY2024FY2025: Operating cash flow −$249MFY2025: Shares issued $1.8BFY2025: Capital spending −$56K$1.8BFY2025
Over these 5 years operating cash flow totalled −$802M; the largest uses were operating cash flow ($802M) and capital spending ($1.6M). Cash-flow statements as filed.

Where the cash came from and went

Praxis Precision Medicines: sources (+) and uses (−) of cash, Q2 2026Praxis Precision Medicines: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$77.5MCash drawn (+) / kept (−)$62.0MOther investing$11.2MOther financing$4.9MTaxes on employees’ shares−$310KCapital spending−$245K
Praxis Precision Medicines: sources (+) and uses (−) of cash, TTM to Q2 2026Praxis Precision Medicines: sources (+) and uses (−) of cash, TTM to Q2 2026Shares issued$3.0BOther financing−$1.8BOther investing−$611MCash drawn (+) / kept (−)−$317MOperating cash flow−$305MTaxes on employees’ shares−$14.1MCapital spending−$307K

From profit to cash

Praxis Precision Medicines: net income to operating cash flow, Q2 2026Praxis Precision Medicines: net income to operating cash flow, Q2 2026Net income−$83.7MDepreciation & amortization$33KStock-based pay$11.3MPayables−$7.9MAccrued liabilities$6.9MPrepaid and other assets−$2.9MOperating cash flow−$77.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$77.5M−$245K—$62.0M−$77.8M
Q1 2026−$86.2M−$62K$2.4B−$179M−$86.2M
Q4 2025−$76.3M—$600M−$208M−$76.3M
Q3 2025−$65.1M——$7.9M−$65.1M
Q2 2025−$54.7M−$56K—$8.2M−$54.7M
Q1 2025−$53.0M—$1.2B$49.8M−$53.0M
Q4 2024−$56.1M—$100M−$46.7M−$56.1M
Q3 2024−$27.5M——−$23.5M−$27.5M

Praxis Precision Medicines: income statement and cash flow

Praxis Precision Medicines, Q4 2024: revenue $7.5M (14× year over year), operating margin -857.0%. The chart follows the revenue to costs, profit and cash.

Praxis Precision Medicines: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.